Please login to the form below

Not currently logged in
Email:
Password:

Ariad Pharmaceuticals

This page shows the latest Ariad Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

DDB Remedy and McCann Health among 2016 Rx Club winners

DDB Remedy and McCann Health among 2016 Rx Club winners

Ogilvy CommonHealth Worldwide won the gold prize in the drug education - doctors category, taking home the creativity excellence award for its 'ALK Progression' campaign for Ariad Pharmaceuticals.

Latest news

  • Angelini to market Ariad’s Iclusig in Eastern Europe Angelini to market Ariad’s Iclusig in Eastern Europe

    Angelini to market Ariad’ s Iclusig in Eastern Europe. Comes after leukaemia drug passes EMA safety review. ... US pharma company Ariad Pharmaceuticals has licensed its cancer drug Iclusig to Italy-based firm Angelini Pharma to market in 23 Eastern

  • Ariad cuts 160 jobs in US after Iclusig suspension Ariad cuts 160 jobs in US after Iclusig suspension

    Ariad Pharmaceuticals is to cut 40 per cent of its workforce in the US in order to cope with the suspension of its blood cancer drug Iclusig. ... Following the reduction, Ariad will be left with 295 employees covering both regions.

  • Ariad tanks as Iclusig trial is halted on safety grounds Ariad tanks as Iclusig trial is halted on safety grounds

    Ariad tanks as Iclusig trial is halted on safety grounds. Shares fall after leukaemia patients develop blood clots. ... Investors continued to bail out of Ariad Pharmaceuticals after it was forced to terminate a pivotal trial of its leukaemia drug

  • Boehringer's oncology unit scores first EU approval Boehringer's oncology unit scores first EU approval

    Meanwhile, other companies are also vying to bring EGFR-targeting drugs to market for NSCLC, including Ariad Pharmaceuticals with its AP26113 candidate (in phase II) and Clovis Oncology with its

  • Merck withdraws filing for sarcoma drug in Europe Merck withdraws filing for sarcoma drug in Europe

    Merck licensed ridaforolimus from Ariad Pharmaceuticals in 2010 in a $50m deal, and filed for approval of the oral mTOR inhibitor in sarcoma patients who had a favourable response to chemotherapy

More from news
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    acquisition of Ariad Pharmaceuticals. ... Company acquisition. Rare diseases, option to R&D pipeline. 30, 000. Ariad Pharmaceuti-cals.

  • Pharma deals in August 2015 Pharma deals in August 2015

    So it was no surprise that by the end of the month Baxalta was rumoured to be countering with deal activity of its own with discussions to buy Ariad Pharmaceuticals, an ... Immuno-oncology combinations in lung cancer. Not disclosed. Peregrine

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 9, 500. Avanir Pharmaceuticals / Otsuka Pharmaceutical. Portfolio of CNS products, inc Nuedexta marketed for pseudobulbar affect. ... Research collaboration, options to license. 125. †† Ariad Pharmaceuticals / Otsuka

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
FCB Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics